Contact Us
  • Choose License Type

Middle East and Turkey Hemophilia Treatment Market, by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East) is estimated to be valued at US$ 645.1 million in 2019, and is expected to exhibit a CAGR of 4.2%, during the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Middle East and Turkey hemophilia treatment market is expected to witness significant growth, owing to increasing adoption of collaborations and acquisitions strategies by market players and rising initiatives by governments and market players to offer cost-effective hemophilia treatment. For instance, in February 2019, F. Hoffmann-La Roche AG participated in World Federation of Hemophilia (WFH) Humanitarian Aid Program and donated Hemlibra to 1,000 patients suffering from hemophilia A in emerging economies.

Browse 21 Market Data Tables and 20 Figures spread through 185 Pages and in-depth TOC on " Middle East and Turkey Hemophilia Treatment Market, by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East) - Global Forecast to 2027"

To know the latest trends and insights related to Middle East and Turkey Hemophilia Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/middle-east-and-turkey-hemophilia-treatment-market-3250

Several key players in the market are focused on receiving approval for their novel products and launching them into the market. Approval and launches of such novel products in the market is expected to create a lucrative environment for growth of Middle East and Turkey hemophilia treatment market over the forecast period. For instance in June 2019, Novo Nordisk received marketing authorization from European commission for Esperoct in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency) In April 2019, Roche Products India Pvt Ltd launched its hemophilia A drug emicizumab, branded as Hemlibra in India. It is indicated as a prophylactic treatment for reducing the frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors.

Key players are focused on development of novel drug delivery therapy for treatment of hemophilia, and this is expected to create a lucrative opportunity for key players to provide advance drug delivery system. For instance, in 2016, researchers from the Cockrell School of Engineering at The University of Texas, Austin, developed biodegradable delivery system, A capsule for people suffering from Factor VIII deficiency. It contains micro and nanoparticles, to carry a protein therapy that treats hemophilia.

Key Takeaways of the Middle East and Turkey Hemophilia Treatment Market:

  • The Middle East and Turkey hemophilia treatment market is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027), owing to increasing product launches for treating hemophilia by key players. For instance, in May 2018, Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche Group, launched its anti-coagulation factor IXa/X humanized biospecific monoclonal antibody/coagulation factor VIII substitute, HEMLIBRA for routine prophylaxis, to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors.
  • Increasing clinical trials by key players on hemophilia treatment is expected to drive the Middle East and Turkey hemophilia treatment market growth over the forecast period. For instance, in February 2019, Takeda Pharmaceutical Company Limited announced results from its phase IIIb/IV clinical trial for ADYNOVATE, a recombinant antihemophilic factor at the 12th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD), Prague, Czech Republic.
  • Major players operating in the Middle East and Turkey hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner